Concord Wealth Partners Celldex Therapeutics, Inc. Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 8 shares of CLDX stock, worth $186. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8Holding current value
$186% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
189Shares Held
69.3MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$195 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$152 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$110 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$91 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$87.7 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.09B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...